leflunomide has been researched along with Abnormalities, Congenital in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-four pregnant women with rheumatoid arthritis (RA) who were treated with leflunomide during pregnancy (95." | 7.76 | Birth outcomes in women who have taken leflunomide during pregnancy. ( Braddock, SR; Chambers, CD; Jin, S; Johnson, DL; Jones, KL; Lopez-Jimenez, J; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2010) |
| "Birth defects were reported in 44 babies/fetuses/embryos from 587 pregnancies, with 2 reporting at least 3 minor defects and 20 reporting major defects." | 5.56 | Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. ( Afsar, S; Davenport, L; Henson, LJ; Poole, EM; Purvis, A; Truffinet, P, 2020) |
| "Sixty-four pregnant women with rheumatoid arthritis (RA) who were treated with leflunomide during pregnancy (95." | 3.76 | Birth outcomes in women who have taken leflunomide during pregnancy. ( Braddock, SR; Chambers, CD; Jin, S; Johnson, DL; Jones, KL; Lopez-Jimenez, J; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2010) |
| "Birth defects were reported in 44 babies/fetuses/embryos from 587 pregnancies, with 2 reporting at least 3 minor defects and 20 reporting major defects." | 1.56 | Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. ( Afsar, S; Davenport, L; Henson, LJ; Poole, EM; Purvis, A; Truffinet, P, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Henson, LJ | 1 |
| Afsar, S | 1 |
| Davenport, L | 1 |
| Purvis, A | 1 |
| Poole, EM | 1 |
| Truffinet, P | 1 |
| Chambers, CD | 1 |
| Johnson, DL | 1 |
| Robinson, LK | 1 |
| Braddock, SR | 1 |
| Xu, R | 1 |
| Lopez-Jimenez, J | 1 |
| Mirrasoul, N | 1 |
| Salas, E | 1 |
| Luo, YJ | 1 |
| Jin, S | 1 |
| Jones, KL | 1 |
| Østensen, M | 1 |
| von Esebeck, M | 1 |
| Villiger, PM | 1 |
3 other studies available for leflunomide and Abnormalities, Congenital
| Article | Year |
|---|---|
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide.
Topics: Adult; Congenital Abnormalities; Crotonates; Female; Humans; Hydroxybutyrates; Immunosuppressive Age | 2020 |
Birth outcomes in women who have taken leflunomide during pregnancy.
Topics: Adult; Anticholesteremic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Birth Weight; Body Siz | 2010 |
Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Congenital Abnormalities; Cont | 2007 |